32results about How to "Lower viral load" patented technology

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

The invention discloses compounds having virus resistance and a composition thereof. The composition comprises one or more of the 13 compounds comprising 6'-O-caffeoyl deacetyl asperulosidic acid methyl ester. The compounds having virus resistance and the composition thereof can be extracted from plants and can also be prepared by synthesis. The composition comprising the compounds having virus resistance can prevent and treat viral infection-caused diseases such as influenza, myocarditis, conjunctivitis, viral pneumonia, encephalitis, leukemia, hepatitis B, hepatitis C, AIDS, genitourinary system infection, EB virus infection, human papillomavirus infection and cytomegalovirus infection. The composition can be prepared into an oral preparation, an injection, a spray, a subcutaneous injection and an anus suppository.

The invention discloses a recombinant novel coronavirus (SARS-CoV-2) vaccine composition. The vaccine composition comprises a recombinant spike protein with an amino acid sequence shown in SEQ ID NO:1. The vaccine composition further comprises a pharmaceutically acceptable carrier, such as an aluminum adjuvant in combination with a CpG ODN adjuvant. The vaccine composition shows excellent immunogenicity in mice, and can induce an organism to generate high-titer antibody response biased to Th1 and high-level cellular immune response. Animal model experiments show that the vaccine composition can induce high-titer neutralizing antibodies and significantly reduce the viral load inside lung and turbinate tissues.

According to the invention, coronavirus spike protein RBD specific memory B cells are separated from PBMC of a rehabilitation person infected by a new coronavirus, amplification is carried out to obtain antibody light and heavy chain variable region sequences, a carrier is connected and introduced, recombinant expression is carried out to obtain a recombinant human monoclonal antibody, a monoclonal antibody which has high affinity with SARS-CoV-2 spike protein RBD, strong blocking force on the SARS-CoV-2 spike protein RBD and a host receptor ACEII and strong neutralizing activity on virus infected cells is selected from the monoclonal antibody, further screening is performed the ADE effect of the monoclonal antibody, and finally an anti-SARS-CoV-2S protein specific antibody MW07 which does not generate an ADE phenomenon is obtained.

The invention provides a novel coronavirus main protease inhibitor as well as a preparation method and application thereof. Specifically provided is a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or an optical isomer thereof, or an isotope substitution form thereof. The compound can be used for effectively inhibiting the activity of SARS-CoV-2 Mpro, and can be used for preparing an SARS-CoV-2 Mpro inhibitor to block the replication and transcription of SARS-CoV-2 virus in the body of a patient. The compound disclosed by the invention has a very good application prospect in the preparation of an SARS-CoV-2 Mpro inhibitor, an SARS-CoV-2 resisting medicine and a medicine for preventing and / or treating novel coronavirus pneumonia.

The invention discloses a drug delivery system for external use containing the effective composition of bullatacin locality drug; the effective composition containing the bullatacin locality drug is dissolved in a mixed liquid of absolute alcohol and propylene glycol and fully stirred and mixed, and then prepared into the drug delivery system for external use; the drug delivery system comprises a patch, an aerosol or a film agent. Adoptions of the natural substance bullatacin extracted from cherimoya and an external using manner of the invention overcomes the shortcoming that the antitumor drugs and anti-AIDS drug have to be orally used or intravenously medicated, and the drug delivery system can ensure the drug to be absorbed through the skin, thus slowly releasing the drug and reducing the delivery dosage of the drug and the economic cost for the treatment.

The invention discloses a porcine epidemic diarrhea virus vaccine strain and a preparation method thereof. The vaccine strain is obtained by continuously transmitting FJzz1 to 200 generations in Vero cells. Low-generation FJzz1-F20 and high-generation FJzz1-F200 strains are selected to perform pathogenicity evaluation on piglets, and the result shows that the clinical manifestation of the piglets in a high-generation FJzz1-F200 infection group is obviously lighter than that of the piglets in an FJzz1-F20 infection group, and the diseased pigs do not die. Compared with the FJzz1-F20 infection group, the excrement toxin expelling amount of the piglets in the FJzz1-F200 infection group and the viral load in intestinal tissues are remarkably reduced, and the intestinal tissues are not subjected to obvious histopathological changes. Meanwhile, detection finds that the FJzz1-F200 infection group can induce high-level I-type and III-type interferon generation in the intestinal tissues. The research result shows that the FJzz1-F200 is weak in pathogenicity and has the potential of serving as a PEDV candidate attenuated vaccine strain.

The embodiment of the invention provides application of a lung-ventilating and toxin-vanquishing prescription or an extract of the lung-ventilating and toxin-vanquishing prescription to preparation of a medicine for preventing and / or treating pneumonia caused by influenza A virus H1N1, wherein the lung-ventilating and toxin-vanquishing prescription comprises the following components in parts by weight: 5-7 parts of raw ephedra, 28-32 parts of gypsum, 28-32 parts of raw coix seeds, 13-17 parts of bitter apricot kernels, 8-12 parts of rhizoma atractylodis lanceae, 13-17 parts of pogostemon cablin, 10-14 parts of artemisia apiacea, 28-32 parts of dried rhizoma phragmitis, 13-17 parts of pummelo peel, 18-22 parts of polygonum cuspidatum, 28-32 parts of verbena, 13-17 parts of semen lepidii and 8-12 parts of raw liquorice. The lung-ventilating and toxin-vanquishing prescription and the extract thereof provided by the invention can reduce the virus load, reduce the expression of proinflammatory factors, promote the expression of anti-inflammatory factors and improve pulmonary symptoms, so that the lung-ventilating and toxin-vanquishing prescription and the extract thereof can be used for preventing and / or treating pneumonia caused by the influenza A virus H1N1.

The invention relates to applications of a beta-glucan extract product in the immunological enhancement of poultry animals, and specifically provides a kit. The kit includes as follows: (1) an immune-enhancer used for enhancing the immunity of poultry animals and includes a beta-glucan extract product extracted from saccharomyces cerevisiae cell walls; and (2) a virus vaccine. Applications of thebeta-glucan extract product extracted from the saccharomyces cerevisiae cell walls in the preparation of the kit and immune-enhancer for enhancing the immunity of the poultry animals are also provided. Immunological enhancement can be performed on the poultry animals by using the beta-glucan extracted from the saccharomyces cerevisiae cell walls, so that lymphocyte proliferative response and T cell response of the poultry animals inoculated with the vaccine can be enhanced; viral load can be reduced; pathogenic rates or mortality can be lowered; antibodies can be generated in advance; antibodyproduction can be enhanced; and / or the diffusion of viruses can be restricted.

The invention discloses an anti-HPV infection medicine, which comprises the following raw material medicines in parts by weight: 10-20 parts of radix sophorae flavescentis, 10-20 parts of phellodendron amurense, 6-12 parts by weight of cortex dictamn, 4-8 parts by weight of safflower; 2-4 parts by weight of fructus cnidii; 3-5 parts by weight of Radix Astragali; 2-4 parts by weight of aloe; and 0.5-3 parts by weight of bunge corydalis herb. The invention discloses the anti-HPV infection medicine, the clinical symptoms and signs of patients can be obviously improved; the virus load capacity ofa virus infected person is effectively reduced; the medicine for treating the heart disease is prepared from the following raw materials: radix sophorae flavescentis, phellodendron amurense, cortex dictamni, safflower, fructus cnidii, Radix Astragali, aloe, bunge corydalis herb, borneol, perilla stems, eupatorium, campsis grandiflora, ground beetle, cortex magnoliae officinalis, rhinacanthus nasutus and rhizoma alismatis. Through reasonable compatibility of all the raw materials, the special performance and effects of all the raw materials are fully exerted, meanwhile, the complementary effectof all the raw materials is considered, the medicine effects supplement each other, the condyloma acuminatum treatment effect is remarkable, and no toxic or side effect exists.

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

The invention discloses an anti-AIDS virus bullatacin patch for external use, which comprises a backing layer, a drug reservoir and an anti-sticking layer; a cotton medicinal non-woven fabrics with good permeability is used as the backing layer, a polymeric gel (an acrylate pressure-sensitive gel) as an adhesive; the patch comprises the prepared liquid of bullatacin, and a silicone-oil anti-sticking polyester film is functioned as an anti-sticking layer. The patch for external use has the advantages that not only the disadvantage of serious harmful and side effects of the existing oral or intravenous antitumor drug are solved, but also the disadvantage of heavy skin irritation and a certain extend of toxicity of traditional patches for external use are overcome, and the economic cost is reduced.

The present invention provides a new vector for gene therapy said vector being therapeutically very efficient, viral particles comprising said vector, compositions comprising said viral particle, uses thereof, methods for the preparation of the vector), and therapies using said vector.

The invention belongs to the technical field of medicines, and discloses application of a compound in preparation of an antiviral drug. The compound N-[(2-methoxyphenyl) methyl]-2-[4-(4-methoxyphenyl)-2-oxybenzopyran-7-yl] oxyacetamide has a new application in medicine, and the application refers to a new application in virus resistance, especially in the aspect of pneumonia caused by coronavirus. The invention proves that the compound has the effects of remarkably inhibiting the lung index and reducing the lung virus load, and the effect of the compound is superior to that of a positive drug chloroquine phosphate and Lanhuaqing pestilence. The action mechanism of the compound for resisting viral pneumonia is related to the aspects of regulating expression of inflammatory factors, regulating differentiation of immune cells, inhibiting generation of free radicals and the like. The N-[(2-methoxyphenyl) methyl]-2-[4-(4-methoxyphenyl)-2-oxybenzopyran-7-yl] oxyacetamide can be used as a safe and effective novel clinical candidate drug for resisting viruses.

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

The invention discloses a drug delivery system for external use containing the effective composition of bullatacin locality drug; the effective composition containing the bullatacin locality drug is dissolved in a mixed liquid of absolute alcohol and propylene glycol and fully stirred and mixed, and then prepared into the drug delivery system for external use; the drug delivery system comprises apatch, an aerosol or a film agent. Adoptions of the natural substance bullatacin extracted from cherimoya and an external using manner of the invention overcomes the shortcoming that the antitumor drugs and anti-AIDS drug have to be orally used or intravenously medicated, and the drug delivery system can ensure the drug to be absorbed through the skin, thus slowly releasing the drug and reducing the delivery dosage of the drug and the economic cost for the treatment.

The present invention provides a compound of general formula I: and pharmaceutically acceptable salts and esters thereof. The provided compounds, compositions and methods are useful in the treatment of viral infections, particularly hepatitis C infections.

The invention relates to a plant composition for the treatment or prevention of viral blood-borne diseases such as the diseases caused by the human immunodeficiency virus (HIV) or hepatitis C. According to the invention, the composition mainly includes flower of sulphur, a plant which contains catechins and a tannin agent, as well as a pharmaceutically acceptable medium. The invention also relates to the method for manufacturing said composition. The invention can be used in the field of treating or preventing viral blood-borne diseases such as the diseases caused by the human immunodeficiency virus (HIV) or hepatitis C.

The invention belongs to the field of medicine application and in particular relates to application of an AMPK (Adenosine 5'-monophosphate-activated protein kinase) agonist A769662 in preparing a medicine for treating porcine reproductive and respiratory syndromes. The invention finds that the AMPK agonist A769662 is capable of effectively inhibiting duplication of viruses of the porcine reproductive and respiratory syndromes, capable of remarkably alleviating clinical symptoms, reducing morbidity and mortality and reducing viral loads of pig tissue, and makes a basis for later research and development of medicines for treating the porcine reproductive and respiratory syndromes.

The invention belongs to the technical field of medicines and particularly relates to an artemisia-honeysuckle-flower-fructus gardeniae enema and a preparation method and application thereof. The enema is prepared from the following medicinal raw materials in parts by weight: 3-15 parts of honeysuckle flowers, 6-25 parts of artemisia apiacea and 1-2.99 parts of fructus gardeniae. The enema has theeffect of resisting CV-A6 and can be used for treating hand-foot-and-mouth diseases caused by CV-A6 infection.

The invention discloses novel application of azidothymidine in treating leukaemia. Pharmacodynamic experiments show that the azidothymidine has functions of inhibiting the growth of human leukaemia cells Jukat and murine leukemia cells L615, can inhibit the infiltrations of mouse peripheral blood, marrow and liver and spleen organizations, remarkably prolong the life cycle of a leukaemia mouse, and effectively reduce the leucovirus load of a Friend mouse spleen, and has significant effect on treating acute erythroleukemia induced by Friend mouse leucovirus.

The invention discloses a high-efficiency breeding method for Lanzhou lily seedlings. The Lanzhou lily seedlings are used as explants, and the seedlings are subjected to the steps of seed collection, sterilization, germination, at least one propagation culture, strong seedling culture and bulb expansion culture. , to prepare lily seedlings. The beneficial effects of the invention are as follows: the invention uses seed germination instead of scale cuttings to produce seedlings, blocks the intergenerational spread and accumulation of viruses caused by scale cuttings, and significantly reduces the viral load of lily seedlings compared with the prior art , improve the heterogeneity of the seedling population, and effectively solve the defects of virus accumulation and narrow genetic background caused by asexual reproduction in Lanzhou lily seedling propagation. The breeding method can be used for the preservation of Lanzhou lily germplasm resources and the factory breeding of seedlings, which is beneficial to the breeding of new Lanzhou lily varieties, the rapid popularization of excellent varieties, the preservation and innovation of germplasm resources, and the improvement of the yield and quality of Lanzhou lily. .

The present invention provides a compound of formula I: and pharmaceutically acceptable salts and esters thereof. The provided compounds, compositions and methods are useful for treating viral infections, especially hepatitis C virus infections.

The invention relates to an anti-virus Chinese herbal medicine product, wherein Chinese medicinal herbs or their extracts are employed as the raw material, which can be used for antiviral, in particular the treatment of HIV / AIDS. The invention also relates to the method for treating viral infection of homothermal animal by employing the medicinal product. The invention also relates to the process for preparing the product and the compostion.

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

The invention provides an HSV-2 DNA vaccine used by mucous membranes. The HSV-2 DNA vaccine comprises pgD, pCCL28 and immune mediators, wherein the pgD is a pcDNA3.1(+) plasmid including a nucleotide sequence of HSV-2 gD envelope glycoprotein; the pCCL28 is a pcDNA3.1(+) plasmid including a nucleotide sequence of CCL28; and the vaccine is immunized or used by the mucous membranes. The invention also provides a preparation method of the vaccine. In addition, the invention provides an application of the vaccine in preventing and treating herpes simplex virus infection and treating diseases related to the herpes simplex virus. The HSV-2 DNA vaccine provided by the invention has an ideal immune protection effect and HSV-2 control and disease treatment effects, is convenient in promotion and use, easy in quality control and large-scale production, storage and transportation, low in cost and simple in operation, and has good market application prospects.

The invention relates to the field of medicines and discloses an anti-A(H1N1) flu pharmaceutical composition and application thereof. The pharmaceutical composition comprises marine organisms and a traditional Chinese medicine composition. The efficient and safe pharmaceutical composition prepared from seven natural medicines has an anti-A(H1N1) flu effect, is good in curative effect, has no toxic or side effect and no drug dependence for human bodies, and is superior to the conventional drug preparation product; therefore, the pharmaceutical composition can be widely applied in preparation of an anti-A(H1N1) flu drug.

The invention relates to a compound for treating and / or preventing hepatitis B virus infection as well as a preparation method and application thereof. Specifically, the compound disclosed by the invention has a structure shown as a formula I, and the definitions of all groups and substituents are as described in the specification. The compound has higher activity, better in-vivo drug effect, better safety, better pharmacokinetic property and better druggability.